As a reputable boutique CRO with a strong track record of delivering high-quality, expedited clinical trials in the Asia-Pacific, HiRO's acquisition of Courante Oncology marks a significant milestone in its global expansion. This strategic move further strengthens HiRO's capabilities in managing global studies, extending its presence into the US market.

Courante Oncology brings over 25 years of invaluable experience in the drug development industry. The company's expertise spans all aspects of phase 1-3 clinical trials, ranging from initial feasibility studies and protocol development to site monitoring and closeout visits. Renowned for their dedicated commitment to oncology research and clinical trial management, the Courante team has earned a remarkable reputation in the industry.

The synergy between HiRO and Courante Oncology creates a powerful partnership that will deliver successful clinical trials tailored to meet the evolving needs of the industry. Both companies possess robust clinical research networks, covering the Asia-Pacific region and the US, ensuring a seamless integration of expertise and resources.

"We are thrilled to welcome Courante Oncology into the HiRO family," said Dr. Karen Chu, Founder and CEO of HiRO. "This acquisition allows us to leverage Courante's extensive experience in oncology trials and enhance our capabilities in managing global studies. Together, we strive to deliver best-in-class cross-border solutions and relentless accountability that set us apart in the demanding clinical trial landscape. Our focus remains on accelerating the delivery of innovative medicines with simple, rapid, cost-effective clinical research solutions across the commercialization pathway."

"This marks an exciting chapter for Courante as we join forces with HiRO," said Sheri Smith, President of Courante Oncology. "We are excited to join the HiRO family and collaborate closely with their team. This integration will enable us to further expand our service offerings and functions into the US and beyond. We look forward to collaborating with our clients, to deliver effective, streamlined clinical trial solutions that meet and exceed their expectations."

The acquisition of Courante Oncology represents a significant step forward for HiRO as it continues to solidify its position as a global CRO. With a strengthened presence in the US and expanded capabilities, HiRO is well-positioned to deliver innovative and expedited clinical trial solutions to its clients worldwide.